grant
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 18 Sept 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025AblationAbscissionAdjuvantAdjuvant TherapyAnti-CD47ArchitectureAttenuatedAutomobile DrivingB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBedsBiologic ModelsBiological ModelsCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD47CD47 AntigenCD47 GlycoproteinCD47 geneCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCTCAECancer PatientCancersCell AdhesionCell BodyCellsCellular AdhesionCellular Immune FunctionChemotactic CytokinesClinicalClinical TrialsClone CellsCommon Terminology Criteria for Adverse EventsCommon Toxicity CriteriaCytotoxic ChemotherapyCytotoxic TherapyDependenceDisease-Free SurvivalDoseEarly-Stage Clinical TrialsEngineering / ArchitectureEnteral FeedingEvent-Free SurvivalExcisionExtirpationFrequenciesGerminal CenterHNC patientHNSCCHPV + oropharyngeal carcinomaHPV caused cancerHPV driven cancersHPV induced cancerHPV malignancyHPV mediated oropharynx cancerHPV oropharyngeal cancerHPV positiveHPV positive oropharyngeal cancerHPV positive oropharynx cancerHPV related oropharyngeal cancerHPV related oropharyngeal carcinomaHPV(+)HPV+HPV+ OPCHPV+ cancerHPV+ oropharyngeal cancerHPV-OPCHPV-Related MalignancyHPV-associated cancerHPV-associated malignancyHPV-associated oropharyngeal cancerHPV-driven oropharyngeal cancerHPV-related OPCHPV-related cancerHPV-related oropharyngeal cancerHead and Neck Squamous Cell CarcinomaHeterogeneityHomologous Chemotactic CytokinesHuman Papilloma Virus-Related MalignancyHuman Papilloma Virus-Related Malignant NeoplasmHuman Papilloma Virus-associated cancerHuman Papilloma Virus-associated malignancyHuman Papilloma Virus-related cancerHuman papillomavirus cancerHuman papillomavirus driven oropharyngeal cancerHuman papillomavirus induced cancerHuman papillomavirus malignancyHuman papillomavirus related oropharyngeal carcinomaHuman papillomavirus- related oropharyngeal cancerHuman papillomavirus-Related MalignancyHuman papillomavirus-Related Malignant NeoplasmHuman papillomavirus-associated oropharyngeal cancerImmuneImmune Cell ActivationImmune SurveillanceImmune mediated therapyImmunesImmunocompetentImmunologic SurveillanceImmunologically Directed TherapyImmunoradiotherapyImmunosurveillanceImmunotherapyIn complete remissionIncidenceInduction TherapyInfiltrationIntegrin-Associated ProteinIntercrinesKeytrudaLYT3Lymph Node Reticuloendothelial SystemLymph node properLymphaticLymphatic nodesMER6Malignant NeoplasmsMalignant TumorMeasuresMetastatic/RecurrentModel SystemMorbidityMorbidity - disease rateNEOADJNeck DissectionNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNivolumabNodalOpdivoOperative ProceduresOperative Surgical ProceduresOutcomePD 1PD-1PD-1 antibodyPD-1 antibody therapyPD-1 inhibitorsPD-1 therapyPD1PD1 antibodyPD1 antibody therapyPD1 based treatmentPD1 inhibitorsPathologicPatientsPhasePhase 1 Clinical TrialsPhase I Clinical TrialsPre-Clinical ModelPreclinical ModelsPreclinical dataPrimary NeoplasmPrimary TumorQOLQuality of lifeRadiationRadiation therapyRadioimmunotherapyRadiotherapeuticsRadiotherapyRandomizedRemovalResearchResectableRiskSCCHNSIS cytokinesSafetySentinel Lymph NodeSentinel NodeStructure of germinal center of lymph nodeSurface Antigen Identified by Monoclonal Antibody 1D8SurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalT cell clonalityT cell infiltrationT-CellsT-LymphocyteT-cell receptor clonalityT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTCR clonalityTherapeuticThroat CancerThroat CarcinomaToxic effectToxicitiesTreatment ProtocolsTreatment RegimenTreatment ScheduleTumor AntigensTumor ExpansionTumor ImmunityTumor VolumeTumor-Associated AntigenUnited StatesUpregulationaPD-1aPD-1 therapyaPD-1 treatmentaPD1aPD1 therapyaPD1 treatmentadjuvant treatmentanti programmed cell death 1anti programmed cell death protein 1 inhibitoranti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 inhibitorsanti-PD-1 monoclonal antibodiesanti-PD-1 therapyanti-PD-1 treatmentanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 inhibitorsanti-PD1 monoclonal antibodiesanti-PD1 therapyanti-PD1 treatmentanti-canceranti-cancer immunotherapyanti-programmed cell death 1 therapyanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed cell death protein 1 therapyanti-programmed death-1 antibodyanti-tumor immunityantiPD-1anticancer immunotherapyantigen-specific T cellsantitumor immunityarmattenuateattenuatescancer antigenscancer immunitycancer immunotherapycancer infiltrating T cellscheck point blockadecheckpoint blockadechemo-/radio-therapychemo-radiotherapychemoattractant cytokinechemokinechemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychemotherapycomplete responsecytotoxic CD8 T cellscytotoxic CD8 T lymphocytedesigndesigningdraining lymph nodedrivingenteric feedingfeeding tubegastric feedinghead and neck cancer patienthead and neck squamous carcinomahead and neck squamous cell cancerhuman papillomavirus +human papillomavirus associated malignancyhuman papillomavirus caused cancerhuman papillomavirus driven cancershuman papillomavirus mediated oropharynx cancerhuman papillomavirus positivehuman papillomavirus positive oropharyngeal cancerhuman papillomavirus positive oropharyngeal carcinomahuman papillomavirus positive oropharynx carcinomahuman papillomavirus+ oropharyngeal cancerhuman papillomavirus-associated cancerhuman papillomavirus-related cancerimmune activationimmune check point blockadeimmune checkpoint blockadeimmune competentimmune functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunotherapy for cancerimmunotherapy of cancerimprovedinduction therapiesinhibitorirradiationlymph glandlymph nodeslymphnodesmalignancyneoplasm/cancernovelpembrolizumabphase 1 trialphase 2 trialphase I protocolphase I trialphase II trialpreclinical findingspreclinical informationpresence of HPVpresence of human papillomaviruspreservationprogrammed cell death 1programmed cell death protein 1programmed cell death protein 1 therapyprogrammed death 1radiation treatmentradio-chemo-therapyradio-chemotherapyradiochemotherapyrandomisationrandomizationrandomly assignedregional lymph noderesectionresponsesle2standard of caresurgerysystemic lupus erythematosus susceptibility 2thymus derived lymphocytetreatment with radiationtrial comparingtube feedingtumortumor ablationtumor infiltrating T cellstumor-specific antigenαPD-1αPD1
Description preview
Project Summary
HPV mediated oropharynx cancer (HPVOPC) is projected to increase in incidence in the United States over the
next 20 years. Attempts to de-escalate nonsurgical treatment for HPVOPC have not been successful and current
treatment regimens incur significant long-term morbidity. Recently, PD-1 inhibitors received approval as first line…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click